Skip to main content
Caplight Logo









Cellbricks Therapeutics

Cellbricks Therapeutics

Private
BerlinHealthcare & Life Scienceshttps://cellbricks-therapeutics.com/

Last Round

Seed

Mar 25, 2026

Total Funding Raised

$10.07M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Cellbricks Therapeutics is a biotechnology company that develops biofabricated human tissue implants for regenerative medicine, reconstructive surgery, and wound healing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, 3D Printing, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

3D bioprintingtissue engineeringregenerative medicinevascularized tissuebiofabricationbiotechbioprinted organsorgan-on-a-chipbiomaterialstissue modelingmedical devicesAI-driven biologypreclinical researchbiotech servicessynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cellbricks Therapeutics Comparables

Compare Cellbricks Therapeutics with similar companies based on industry and business-model similarity.

Cellbricks Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FluidForm Bio
78%
Aspect Biosystems
77%
Trestle Biotherapeutics
76%

Cellbricks Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 25, 2026
SeedSep 5, 2019

Key People

Founding team and executive leadership

Tobias Lam

CTO, Head Of Technology, co-founder

Founding Team

Alexander Leutner

CEO

Executive Team

Simon MacKenzie

Chief Executive Officer

Executive Team

Cellbricks Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 35, 121% of headcount.

  • Mar 25, 2026

    $10M raised in Seed round.

Cellbricks Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cellbricks Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cellbricks Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerlin
Employee Range29
Year FoundedN/A
Last FundingMar 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?